Start:
January 2016
End:
December 2017
Enrollment:
240
Researchers will test the efficacy and safety of the experimental drug RVT-101 in people with dementia with Lewy bodies, including its effect on visual hallucinations.
Minimum Age: 50 Years
Maximum Age: 85 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Who Is the General Study Contact?
For more information about this trial, contact Axovant Clinical Trials at 1-646-677-5778.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: Axovant Sciences Ltd.
Source: ClinicalTrials.gov ID: NCT02669433
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health